QualityStocksNewsBreaks – CytoDyn Inc.’s (CYDY) PRO 140 Assigned Leronlimab as Official Name by USAN Council
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) today announced that the United States Adopted Names (“USAN”) Council has designated leronlimab as the official name for its PRO 140. The investigational new drug has not yet been approved for any indication; however, CytoDyn is exploring partnering and licensing agreements for HIV treatment with intention to pursue use of leronlimab in cancer and other autoimmune diseases. “As we recently announced, we are very pleased with the results of our monotherapy higher dose of leronlimab 700 mg showing an impressive responder’s rate of over 90%,” CytoDyn President and Chief Executive Officer Dr. Nader Pourhassan…